Current Topics in Pharmacology
12:30 PM, Wednesday, January 11, 2006
Room T-473 HSC
Speaker: Selena Schreiber
Topic: Oh Say Can You See... Looking for the Causes and Treatment of 'Wet' Age Related Macular Degeneration
Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004 Dec 30;351(27):2805-16.
Gonzales CR; VEGF Inhibition Study in Ocular Neovascularization (V.I.S.I.O.N.) Clinical Trial Group. Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: an exploratory analysis. Retina. 2005 Oct-Nov;25(7):815-27.
Vinores SA, Xiao WH, Aslam S, Shen J, Oshima Y, Nambu H, Liu H, Carmeliet P, Campochiaro PA. Implication of the hypoxia response element of the vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development. J Cell Physiol. 2006 Mar;206(3):749-58.
Hangai M, He S, Hoffmann S, Lim JI, Ryan SJ, Hinton DR. Sequential induction of angiogenic growth factors by TNF-alpha in choroidal endothelial cells. J Neuroimmunol. 2006 Feb;171(1-2):45-56. Epub 2005 Nov 8.
Kulkarni AD, Kuppermann BD. Wet age-related macular degeneration. Adv Drug Deliv Rev. 2005 Dec 13;57(14):1994-2009. Epub 2005 Nov 23.
Fine SL, Martin DF, Kirkpatrick P. Pegaptanib sodium. Nat Rev Drug Discov. 2005 Mar;4(3):187-8.
Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature. 2005 Dec 15;438(7070):967-74.
Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol. 2004 Apr;122(4):598-614. Review.
2005-2006 Journal Club Schedule